Mammary Cell News Volume 8.40 | Oct 13 2016

TOP STORY

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

In this randomized, placebo-controlled, Phase III trial, the authors evaluated the efficacy and safety of the selective CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease. [N Engl J Med] Full Article | Press Release

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

The Degradation of EZH2 Mediated by LncRNA ANCR Attenuated the Invasion and Metastasis of Breast Cancer

Scientists reported the discovery of ANCR modulating the stability of the enhancer of zeste homolog 2 (EZH2), and in the invasion and metastasis of breast cancer cells. [‎Cell Death Differ] Abstract

Impairment of DYRK2 Augments Stem-Like Traits by Promoting KLF4 Expression in Breast Cancer

Investigators showed that dual-specificity tyrosine phosphorylation-kinase 2 (DYRK2) is a novel negative regulator for formation of breast cancer stem cells. [Oncogene] Abstract

Physical Interaction of Estrogen Receptor with MnSOD: Implication in Mitochondrial O₂^.− Upregulation and mTORC2 Potentiation in Estrogen-Responsive Breast Cancer Cells

Scientists showed estrogen receptor-dependent transient inhibition of manganese superoxide dismutase (MnSOD) catalytic function in breast cancer cells. [Oncogene] Abstract

New Potential Beneficial Effects of Actein, a Triterpene Glycoside Isolated from Cimicifuga Species, in Breast Cancer Treatment

The authors investigated the in vitro and in vivo effects of actein on angiogenesis using human microvascular endothelial cells, matrigel plug and tumor-bearing mouse models. [Sci Rep] Full Article

LPIN1 Promotes Epithelial Cell Transformation and Mammary Tumorigenesis via Enhancing Insulin Receptor Substrate 1 Stability

Researchers demonstrated that LPIN1 enhances the tumor-promoting function of insulin receptor substrate 1 (IRS1) by controlling IRS1 stability. LPIN1 interacts with IRS1 in an insulin growth factor-1-dependent signaling pathway and inhibits its serine phosphorylation, and thereby eliminating ubiquitin-dependent degradation of IRS1 via proteasomal and lysosomal pathways. [Carcinogenesis] Abstract

Plumbagin Suppresses the Invasion of HER2-Overexpressing Breast Cancer Cells through Inhibition of IKKα-Mediated NF-κB Activation

The authors showed that plumbagin inhibited the transcriptional activity of nuclear factor-κB (NF-κB) in HER2-positive breast cancer cells. [PLoS One] Full Article

Intrinsic Resistance to 5-Fluorouracil in a Brain Metastatic Variant of Human Breast Cancer Cell Line, MDA-MB-231BR

Investigators found that MDA-MB-231BR, a brain metastatic variant of a human breast cancer cell line, was refractory to treatment with 5-fluorouracil even without chronic drug exposure, compared to its parent cell line, MDA-MB-231, and a bone metastatic variant, MDA-MB-231SCP2. [PLoS One] Full Article

The DNA Cytosine Deaminase APOBEC3B Promotes Tamoxifen Resistance in ER-Positive Breast Cancer

Researchers used clinical data and xenograft experiments to ask whether APOBEC3B contributes to ongoing breast tumor evolution and resistance to the selective estrogen receptor modulator, tamoxifen. [Sci Adv] Full Article | Press Release

CLINICAL RESEARCH

SAKK 24/09: Safety and Tolerability of Bevacizumab plus Paclitaxel vs. Bevacizumab plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients with HER2-Negative Advanced Stage Breast Cancer – a Multicenter, Randomized Phase III Trial

Scientists aimed to demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared with paclitaxel/bevacizumab. [BMC Cancer] Full Article

Lapatinib Resistance in HER2⁺ Cancers: Latest Findings and New Concepts on Molecular Mechanisms

The authors provide scientific support for molecular targeted therapies in HER2⁺ cancers and discuss the latest findings and new concepts on molecular mechanisms underlying lapatinib resistance. [Tumor Biol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Fulvestrant Demonstrates Progression-Free Survival Advantage in 1^st Line Advanced Breast Cancer

AstraZeneca announced data from the Phase III FALCON trial demonstrating superior median progression-free survival for fulvestrant 500mg compared to anastrozole 1mg in the 1^st line treatment of postmenopausal women with locally-advanced or metastatic breast cancer, who have not had prior hormonal treatment for hormone receptor positive breast cancer. [Press release from AstraZeneca (Business Wire, Inc.) discussing research presented at the 2016 European Society for Medical Oncology (ESMO) Congress, Copenhagen] Press Release

PharmaMar Announces Positive Results from Its Phase II Study with Lurbinectedin in BRCA 1/2 -Associated Metastatic Breast Cancer at the ESMO 2016 Congress

PharmaMar has announced the positive results of its Phase II study of lurbinectedin in patients with BRCA 1/2 – associated metastatic breast cancer, who had previously received a maximum of three prior chemotherapy regimens. [Press release from PharmaMar discussing research presented at the 2016 European Society for Medical Oncology (ESMO) Congress, Copenhagen] Press Release

Multiple Oncotype DX^® Presentations Reinforce Its Unique Clinical Utility with Prospective Outcomes Results in Over 63,000 Breast Cancer Patients

Genomic Health, Inc. announced results from eight Oncotype DX^® Breast Recurrence Score™ presentations highlighting clinical evidence in identifying which patients with node-negative and node-positive invasive breast cancer should be treated with chemotherapy. [Press release from Genomic Health, Inc (PR Newswire Association LLC) discussing research presented at the 2016 European Society for Medical Oncology (ESMO) Congress, Copenhagen] Press Release

Daiichi Sankyo Presents Late-Breaking Phase I Data for Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a in T-DM1 Pre-Treated Breast Cancer

Daiichi Sankyo Company, Limited announced safety and preliminary efficacy data from a Phase I study of DS-8201a, a novel investigational HER2-targeting antibody drug conjugate, which suggest that it was well-tolerated with no dose-limiting toxicities. [Press release from Daiichi Sankyo Company, Limited discussing research presented at the 2016 European Society for Medical Oncology (ESMO) Congress, Copenhagen] Press Release

Novartis’ HR+/HER2- Advanced Breast Cancer Trial Gives Superior Progression-Free Survival

Results from the Phase III monaleesa-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. [Novartis Institutes for BioMedical Research] Press Release

Houston Methodist Receives Nearly $4 Million from U.S. Defense Department to Combat Lethal Breast Cancer

Scientists at Houston Methodist received support from the U.S. Department of Defense to reprogram cancer patients’ immune cells to attack triple negative breast cancer. [Houston Methodist] Press Release

Dr. Susan Love Research Foundation Receives $3 Million NCI Grant to Develop Portable Self-Reading Ultrasound for Triage of Palpable Breast Lumps

The National Cancer Institute has awarded a $3 million grant to Dr. Susan Love Research Foundation. The three-year UH3 Phase II exploratory cooperative agreement will support work to further test a computer assisted diagnosis triage software product that can triage palpable breast lumps and identify those that are suspicious. [Dr. Susan Love Research Foundation (PR Newswire Association LLC)] Press Release

Merck Announces Recipients of Third Annual €1 Million ‘Grant for Oncology Innovation’ Award

Merck announced the recipients of the 2016 Grant for Oncology Innovation, who will share a €1 million grant to progress their respective research initiatives. The three winning proposals, which focus on breast cancer, colorectal cancer and lung cancer, were selected from a total of 405 applications representing 49 countries. [Merck & Co., Inc] Press Release

Grant Awards: Diversity Boost

A recruitment and retention program launched by the Howard Hughes Medical Institution in Chevy Chase, Maryland, aims to reduce barriers for women and under-represented minorities who seek academic-research careers in the life sciences. [Nature Careers] Editorial

Investors Flee as Firm Scraps RNA-Interference Drug Candidate

A prominent developer of drugs that use RNA interference has abandoned one of its leading candidates amid safety concerns — sending a fresh wave of worry through a field that has long struggled to bring treatments to market. [Nature News] Editorial

The Many Shades of European Postdoc Funding

Finding the right grant or fellowship to fund a postdoc can be a challenge, and the situation is all the more complex in Europe, where academic systems, career prospects, and living costs vary widely among countries. [Science Careers] Editorial

NEW Gordon Research Conference – Mammary Gland Biology
June 11-17, 2017
Stowe, United States

Visit our events page to see a complete list of events in the community.

NEW Research Fellow – DNA Repair and Stem Cell Biology (Mayo Clinic)

NEW Research Associate – Patient-Derived Organoid Models of Breast Cancer (King’s College London)

Postdoctoral Fellow – BioMarker Research Cancer (Houston Methodist Research Institute)

Post Doctoral Associate – Mammary Stem Cell and Cancer Biology (University of Miami)

Post Doctoral Position – Neovascularization and Cancer Biology (The Ohio State University)

Postdoctoral Associate – Functional Genomics and Cancer (The Jackson Laboratory)

Assistant Professor – Physiology and Biophysics (University of Illinois at Chicago)

Postdoctoral Position or Internship – Cancer Research (Stanford University)

Postdoctoral Researcher – Breast Cancer (Purdue University)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.